Synkrino develops novel drug candidates across diverse modalities like gene therapy and mRNA treatments, bridging the gap between scientific discovery and clinical application. The company streamlines the drug development pathway for conditions such as osteoarthritis, obesity, and immuno-resistant cancers, aiming to accelerate the delivery of impactful science to patients.
Funding
Funding not disclosed
Founders
Product
Problem
Numerous promising scientific discoveries in medicine fail to progress beyond the laboratory due to development hurdles and inconsistent financing. This bottleneck delays the availability of innovative treatments for patients and limits the realization of potential therapeutic advancements.
Solution
Synkrino addresses this gap by developing novel drug candidates across diverse modalities and indications, including gene therapy, mRNA treatments, and peptide-based therapies. The company employs proprietary selection, investment, and divestment mechanisms to bridge the transition from early-stage scientific breakthroughs to clinical application. Synkrino focuses on advancing therapeutic assets for conditions such as osteoarthritis, obesity, diabetes, immuno-resistant cancers, and congenital pediatric diseases. By streamlining the development pathway, Synkrino aims to accelerate the delivery of impactful science to patients.
Target Audience
Synkrino targets pharmaceutical companies and biotechnology firms seeking to license or acquire novel drug candidates and therapeutic platforms.
Features
- Development of therapeutic assets utilizing modalities including gene therapy, mRNA, peptides, monoclonal antibodies (mAbs), protein degraders, bicyclic peptides, macrocycles, GAG mimetics, and small molecules.
- Portfolio includes drug candidates targeting indications such as Osteo-Arthritis, Obesity, Diabetes and Cardiometabolic Diseases, Immuno-Resistant Tumors, Non-Small Cell Lung Cancer (NSCLC), Microvillous Inclusion Disease, Systemic Sclerosis (SSc), and Lung Fibrosis.
- Rigorous scientific and commercial diligence process applied to over 100 early-stage biotech programs.
- Network of over 41 pharmaceutical experts with combined experience exceeding 500 years in drug research and development across various therapeutic areas.
- Focus on developing treatments for diseases with significant unmet medical needs, including neurodegenerative diseases and oncology.